

Please Join Us for a Non-CME Industry Session (ISS05) Financially Supported by Bristol Myers Squibb during the 37th ECNP Congress

A FOCUSED APPROACH:

# Targeting Muscarinic Receptors in Schizophrenia

Examine how the neurocircuitry and pathophysiology implicated in the symptoms of schizophrenia have evolved in recent years. This program will shed light on the potential relevance of muscarinic receptors in schizophrenia.

Sunday, September 22, 2024 | 8:30-10:00 AM CET

Allianz MiCo | Brown Hall 1-2

Refreshments will be available



**Celso Arango, MD, PhD**

Chair, Department of Child and Adolescent Psychiatry  
Hospital General Universitario Gregorio Marañón  
Complutense University  
Madrid, Spain



**Silvana Galderisi, MD, PhD**


Professor of Psychiatry  
Chair, Department of Mental and Physical Health and Preventive Medicine  
University of Campania Luigi Vanvitelli  
Naples, Italy

*Speakers are paid consultants of Bristol Myers Squibb*



BSMedical.com

For more information please visit [BSMedical.com](https://www.BSMedical.com)



Meal is provided by Bristol Myers Squibb. Bristol Myers Squibb may not provide meals to certain persons at this event. By accepting a meal at this event, you represent that none of these apply to you: (1) Minnesota or New Jersey provider; (2) healthcare provider licensed in Vermont; or (3) anyone prohibited from accepting things of value such as food or drink at this event by state or federal law, or by your employer's policies. In accordance with the PhRMA Code on Interactions with Health Care Professionals, attendance at this program is limited to healthcare professionals, therefore attendance by guests or spouses is not permitted. Bristol Myers Squibb thanks you for your understanding. Industry Session financially supported by Bristol Myers Squibb during the 37th ECNP Congress. Does not necessarily reflect the opinions of ECNP.

© 2024 Karuna Therapeutics, Inc., a Bristol Myers Squibb company. NS-US-2400239 7/24